Moore, Kathleen

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

Liu, J., Lichtenberg, T., Hoadley, K. A., Poisson, L. M., Lazar, A. J., Cherniack, A. D., Kovatich, A. J., Benz, C. C., Levine, D. A., Lee, A. V., et al. (2018) · Cell

Cancer Genomics and DiagnosticsGene expression and cancer classification

Cited by 3,725

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 2,870

Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer

Hoadley, K. A., Yau, C., Hinoue, T., Wolf, D. M., Lazar, A. J., Drill, E., Shen, R., Taylor, A. M., Cherniack, A. D., Thorsson, V., et al. (2018) · Cell

Cancer Genomics and DiagnosticsGene expression and cancer classification

Cited by 2,546

Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation

Malta, T. M., Sokolov, A., Gentles, A. J., Burzykowski, T., Poisson, L., Weinstein, J. N., Kamińska, B., Huelsken, J., Omberg, L., Gevaert, O., et al. (2018) · Cell

Cancer Cells and MetastasisPluripotent Stem Cells Research

Cited by 2,180

Overall survival with maintenance Olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial

DiSilvestro, P., Banerjee, S., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., et al. (2023) · Journal of Clinical Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 511

Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics

Ding, L., Bailey, M. H., Porta-Pardo, E., Thorsson, V., Colaprico, A., Bertrand, D., Gibbs, D. L., Weerasinghe, A., Huang, K.-L., Tokheim, C., et al. (2018) · Cell

Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer

Cited by 399

PARP inhibitors in the Management of Ovarian Cancer: ASCO guideline

Tew, W. P., Lacchetti, C., Ellis, A., Maxian, K., Banerjee, S., Bookman, M., Jones, M. B., Lee, J.-M., Lheureux, S., Liu, J. F., et al. (2020) · Journal of Clinical Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 315

A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53 -mutant Ovarian Cancer

Oza, A. M., Estevez-Diz, M., Grischke, E.-M., Hall, M., Marmé, F., Provencher, D., Uyar, D., Weberpals, J. I., Wenham, R. M., Laing, N., et al. (2020) · Clinical Cancer Research

Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapy

Cited by 129

A two-step convolutional neural network based computer-aided detection scheme for automatically segmenting adipose tissue volume depicting on CT images

Wang, Y., Qiu, Y., Thai, T., Moore, K., Liu, H., & Zheng, B. (2017) · Computer Methods and Programs in Biomedicine

Medical Image Segmentation TechniquesMedical Imaging and Analysis

Cited by 110

Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer

Moore, K. N., O'Malley, D. M., Vergote, I., Martin, L. P., Gonzalez-Martin, A., Malek, K., & Birrer, M. J. (2018) · Gynecologic Oncology

Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapy

Cited by 82

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

Papadopoulos, K. P., Johnson, M. L., Lockhart, A. C., Moore, K., Falchook, G. S., Formenti, S. C., Naing, A., Carvajal, R. D., Rosen, L. S., Weiss, G. J., et al. (2020) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 66

Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).

Banerjee, S. N., Ring, K. L., Van Nieuwenhuysen, E., Fabbro, M., Aghajanian, C., Oaknin, A., Colombo, N., Santin, A., Clamp, A. R., Moore, K. N., et al. (2023) · Journal of Clinical Oncology

Ovarian cancer diagnosis and treatmentOvarian function and disorders

Cited by 38

Abstract P6-11-09: heavily pre-treated breast cancer patients show promising responses in the first in human study of the first-In-class fatty acid synthase (FASN) inhibitor, TVB-2640 in combination with paclitaxel

Brenner, A., Falchook, G., Patel, M., Infante, Jr., Arkenau, H.-T., Dean, E., Borazanci, E., Lopez, J., Moore, K., Schmid, P., et al. (2017) · Cancer Research

Cancer, Lipids, and MetabolismBreast Cancer Treatment Studies

Cited by 19

Correlation of Imaging and Plasma Based Biomarkers to Predict Response to Bevacizumab in Epithelial Ovarian Cancer (EOC)

Buechel, M. E., Enserro, D., Burger, R. A., Brady, M. F., Wade, K., Secord, A. A., Nixon, A. B., Mirniaharikandehei, S., Liu, H., Zheng, B., et al. (2021) · Gynecologic Oncology

Ovarian cancer diagnosis and treatmentCancer Risks and Factors

Cited by 17

Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive Review

Moore, K. N., & Pothuri, B. (2021) · The Cancer Journal

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 9